Article

Risk assessment, screening and prevention of breast cancer: A look at cost-effectiveness

American Society of Breast Disease, Frisco, TX 75034, United States.
Breast (Edinburgh, Scotland) (Impact Factor: 2.38). 08/2010; 19(4):260-7. DOI: 10.1016/j.breast.2010.03.013
Source: PubMed

ABSTRACT

Recent suggestions by the United States Preventive Task Force to change the longstanding guidelines for screening mammography have raised the issue of cost-effectiveness in regards to breast cancer detection. Given the enormous number of women who have had, or who will be diagnosed with breast cancer, it is essential to maintain the quality of care that has been achieved here in the United States while utilizing a cost-effective approach. The following review attempts a close examination of current methods available for risk assessment, screening and prevention programs. These programs must be carefully considered and analyzed prior to implementing cost-saving changes to current clinical standards that have proven successful in decreasing the mortality from breast cancer throughout the world.

Download full-text

Full-text

Available from: Alan B Hollingsworth, Mar 13, 2015
  • Source
    • "This type of inappropriateness increases the emotional burden of patients and cost to society in a way that can be avoided to a larger degree with systematic screening mammography use. Cost-effectiveness studies of screening mammography, assuming that mortality was reduced with 30%, predicted a 16000$ cost per year of life expectancy saved for women aged 50 to 69 years [14]–[15]. In Belgium since 2001 both procedures are reimbursed, independently of their indication. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Context: Health care technological evolution through new drugs, implants and other interventions is a key driver of healthcare spending. Policy makers are currently challenged to strengthen the evidence for and cost-effectiveness of reimbursement decisions, while not reducing the capacity for real innovations. This article examines six cases of reimbursement decision making at the national health insurance authority in Belgium, with outcomes that were contested from an evidence-based perspective in scientific or public media. Methods: In depth interviews with key stakeholders based on the adapted framework of Davies allowed us to identify the relative impact of clinical and health economic evidence; experience, expertise & judgment; financial impact & resources; values, ideology & political beliefs; habit & tradition; lobbyists & pressure groups; pragmatics & contingencies; media attention; and adoption from other payers & countries. Findings: Evidence was not the sole criterion on which reimbursement decisions were based. Across six equivocal cases numerous other criteria were perceived to influence reimbursement policy. These included other considerations that stakeholders deemed crucial in this area, such as taking into account the cost to the patient, and managing crisis scenarios. However, negative impacts were also reported, in the form of bypassing regular procedures unnecessarily, dominance of an opinion leader, using information selectively, and influential conflicts of interest. Conclusions: 'Evidence' and 'negotiation' are both essential inputs of reimbursement policy. Yet, purposely selected equivocal cases in Belgium provide a rich source to learn from and to improve the interaction between both. We formulated policy recommendations to reconcile the impact of all factors identified. A more systematic approach to reimburse new care may be one of many instruments to resolve the budgetary crisis in health care in other countries as well, by separating what is truly innovative and value for money from additional 'waste'.
    Full-text · Article · Oct 2013 · PLoS ONE
  • Source
    • "Routine screening mammograms usually target women aged from 50 to 69 years old (Bryant & Mai, 2011). However, many studies have identified 40 years old as an appropriate age to begin annual mammographic screening (Bryant & Mai, 2011; Lebovic et al., 2010). Besides being a screening and diagnostic device, the mammography is also used as a research tool. "

    Full-text · Chapter · Mar 2012
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Biomarkers are the measurable characteristics of an individual that may represent risk factors for a disease or outcome, or that may be indicators of disease progression or of treatment-associated changes. In general, the process by which biomarkers, once identified, might be translated into clinical practice has received scant attention in recent psychiatric literature. A body of work in diagnostic development suggests a framework for evaluating and validating novel biomarkers, but this work may be unfamiliar to clinical and translational researchers in psychiatry. Therefore, this review focuses on the steps that might follow the identification of putative biomarkers. It first addresses standard approaches to characterizing biomarker performance, followed by demonstrations of how a putative biomarker might be shown to have clinical relevance. Finally, it addresses ways in which a biomarker-based test might be validated for clinical application in terms of efficacy and cost-effectiveness.
    Preview · Article · Jun 2011 · Molecular Psychiatry
Show more